+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Forecast 2024-2030- Product Image
Global Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Forecast 2024-2030- Product Image
Sale

Global Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5716188
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Monoclonal Antibodies Market size was estimated at USD 69.87 billion in 2023, USD 78.60 billion in 2024, and is expected to grow at a CAGR of 12.89% to reach USD 163.28 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Monoclonal Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Monoclonal Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen, Inc., Astrazeneca PLC, Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol Myers Squibb Co., Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GSK PLC, Incyte Corporation, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis AG, Pfizer Inc., Qiagen N.V., Sanofi S.A., Sartorius AG, Seagen Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chimeric
    • Human
    • Humanized
    • Murine
  • Application
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
  • End-user
    • Hospitals
    • Research Institutes
    • Research Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cancer Monoclonal Antibodies Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Monoclonal Antibodies Market?
  3. What are the technology trends and regulatory frameworks in the Cancer Monoclonal Antibodies Market?
  4. What is the market share of the leading vendors in the Cancer Monoclonal Antibodies Market?
  5. Which modes and strategic moves are suitable for entering the Cancer Monoclonal Antibodies Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Monoclonal Antibodies Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of different cancers worldwide
5.1.1.2. Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
5.1.1.3. Increasing drug approvals along with a robust pipeline
5.1.2. Restraints
5.1.2.1. Surging number of withdrawals of monoclonal antibodies
5.1.3. Opportunities
5.1.3.1. Increasing clinical trials of newly developed monoclonal antibodies
5.1.3.2. Collaborative approach for development of cancer monoclonal antibodies
5.1.4. Challenges
5.1.4.1. Regulatory and technical complications associated with manufacture of monoclonal antibodies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Monoclonal Antibodies Market, by Type
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
6.5. Murine
7. Cancer Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Liver Cancer
7.6. Lung Cancer
7.7. Melanoma
8. Cancer Monoclonal Antibodies Market, by End-user
8.1. Introduction
8.2. Hospitals
8.3. Research Institutes
8.4. Research Laboratories
9. Americas Cancer Monoclonal Antibodies Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Monoclonal Antibodies Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Agilent Technologies, Inc.
13.1.3. Amgen, Inc.
13.1.4. Astrazeneca PLC
13.1.5. Bayer AG
13.1.6. Becton, Dickinson and Company
13.1.7. Bio-Rad Laboratories, Inc.
13.1.8. Bristol Myers Squibb Co.
13.1.9. Celldex Therapeutics, Inc.
13.1.10. Eli Lilly and Company
13.1.11. F. Hoffmann-La Roche AG
13.1.12. Gilead Sciences, Inc.
13.1.13. GSK PLC
13.1.14. Incyte Corporation
13.1.15. Johnson & Johnson
13.1.16. Merck & Co.
13.1.17. Merck KGaA
13.1.18. Novartis AG
13.1.19. Pfizer Inc.
13.1.20. Qiagen N.V.
13.1.21. Sanofi S.A.
13.1.22. Sartorius AG
13.1.23. Seagen Inc.
13.1.24. Takara Bio Inc.
13.1.25. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 7. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CANCER MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 11. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 149. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. CANCER MONOCLONAL ANTIBODIES MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amgen, Inc.
  • Astrazeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol Myers Squibb Co.
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK PLC
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Qiagen N.V.
  • Sanofi S.A.
  • Sartorius AG
  • Seagen Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 78.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 163.28 Billion
Compound Annual Growth Rate12.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030 - Product Image

Global Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Global Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Forecast 2024-2030 - Product Image

Global Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Cancer Monoclonal Antibody Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Cancer Monoclonal Antibody Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 255 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Cancer Monoclonal Antibodies Global Market Report 2024 - Product Image

Cancer Monoclonal Antibodies Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.